Prospects for gene therapy for heart failure
- PMID: 10746995
- DOI: 10.1161/01.res.86.6.616
Prospects for gene therapy for heart failure
Abstract
Heart failure represents an enormous clinical challenge in need of effective therapeutic approaches. The possibility of gene therapy for heart failure merits consideration at this time because of improvements in vector technology; cardiac gene delivery; and, most importantly, our understanding of the molecular pathogenesis of heart failure. We will first review recent advances in cardiac gene delivery in animal models and then examine several targets being considered for therapeutic intervention. In this context, gene transfer provides not only a potential therapeutic modality but also an important tool to help validate specific targets. Several interventions, particularly those enhancing sarcoplasmic calcium transport, show promise in animal models of heart failure and in myopathic cardiomyocytes derived from patients. However, bridging the gap between these basic investigative studies and clinical gene therapy remains a formidable task. Early experiments in rodents will need to be extended to large-animal models with clinical-grade vectors and delivery systems to assess both efficacy and safety. On the basis of a foundation of rigorous science and a growing understanding of heart failure pathogenesis, there is reason for cautious optimism for the future.
Similar articles
-
Genetic editing of dysfunctional myocardium.Med Clin North Am. 2003 Mar;87(2):553-67. doi: 10.1016/s0025-7125(02)00175-x. Med Clin North Am. 2003. PMID: 12693739 Review.
-
Targeting calcium cycling proteins in heart failure through gene transfer.J Physiol. 2003 Jan 1;546(Pt 1):49-61. doi: 10.1113/jphysiol.2002.026732. J Physiol. 2003. PMID: 12509478 Free PMC article. Review.
-
Targeted gene transfer in heart failure: implications for novel gene identification.Curr Opin Mol Ther. 2004 Aug;6(4):381-94. Curr Opin Mol Ther. 2004. PMID: 15468597 Review.
-
Gene delivery approaches to heart failure treatment.Expert Opin Biol Ther. 2004 Sep;4(9):1413-22. doi: 10.1517/14712598.4.9.1413. Expert Opin Biol Ther. 2004. PMID: 15335309 Review.
-
Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation.Cardiovasc Res. 2015 Oct 1;108(1):4-20. doi: 10.1093/cvr/cvv205. Epub 2015 Aug 3. Cardiovasc Res. 2015. PMID: 26239654 Free PMC article. Review.
Cited by
-
Cardiomyopathy classification: ongoing debate in the genomics era.Biochem Res Int. 2012;2012:796926. doi: 10.1155/2012/796926. Epub 2012 Aug 8. Biochem Res Int. 2012. PMID: 22924131 Free PMC article.
-
Current strategies for myocardial gene delivery.J Mol Cell Cardiol. 2011 May;50(5):766-76. doi: 10.1016/j.yjmcc.2010.09.003. Epub 2010 Sep 15. J Mol Cell Cardiol. 2011. PMID: 20837022 Free PMC article. Review.
-
Lipidoid mRNA Nanoparticles for Myocardial Delivery in Rodents.Methods Mol Biol. 2017;1521:153-166. doi: 10.1007/978-1-4939-6588-5_10. Methods Mol Biol. 2017. PMID: 27910047 Free PMC article.
-
Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins.J Mol Cell Cardiol. 2007 Apr;42(4):852-61. doi: 10.1016/j.yjmcc.2007.01.003. Epub 2007 Jan 10. J Mol Cell Cardiol. 2007. PMID: 17300800 Free PMC article.
-
Ectopic expression of KCNE3 accelerates cardiac repolarization and abbreviates the QT interval.J Clin Invest. 2002 Apr;109(8):1083-90. doi: 10.1172/JCI15062. J Clin Invest. 2002. PMID: 11956246 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous